Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
-
Published:2023-10-09
Issue:10
Volume:4
Page:1526-1526
-
ISSN:2662-1347
-
Container-title:Nature Cancer
-
language:en
-
Short-container-title:Nat Cancer
Author:
Miyazaki IsaoORCID, Odintsov Igor, Ishida Keiji, Lui Allan J. W.ORCID, Kato MasanoriORCID, Suzuki Tatsuya, Zhang Tom, Wakayama Kentaro, Kurth Renate I., Cheng Ryan, Fujita Hidenori, Delasos Lukas, Vojnic Morana, Khodos Inna, Yamada Yukari, Ishizawa Kota, Mattar Marissa S., Funabashi Kaoru, Chang Qing, Ohkubo Shuichi, Yano Wakako, Terada Ryuichiro, Giuliano ClaudioORCID, Lu Yue Christine, Bonifacio Annalisa, Kunte Siddharth, Davare Monika A.ORCID, Cheng Emily H.ORCID, de Stanchina Elisa, Lovati Emanuela, Iwasawa Yoshikazu, Ladanyi Marc, Somwar RomelORCID
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
|
|